RecruitingNCT00923507
88
studies recruiting now
as of 7 Sept 2026
883
studies registered in total
as of 7 Sept 2026
17
countries with a recruiting site
as of 7 Sept 2026
9 Jul 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT06442475
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
RecruitingPhase 1NCT07691606
A Study of ARC-02 in B-cell NHL
RecruitingPhase 1 / Phase 2NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1 / Phase 2NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 88 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new MALT lymphoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About MALT lymphoma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (MALT1, BIRC3, IGH, FOXP1, BCL10).
Treatments being studied
8 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Chlorambucil (Leukeran)
Phase 3Rituximab (Blitzima)
Phase 2Bortezomib D-Mannitol (Bortezomib accord)
Phase 2Lenalidomide (Lenalidomide accord)
Phase 2Bendamustine
Phase 2Bortezomib
Phase 2Thalidomide (Kevadon)
Phase 2Orelabrutinib (Innobruka)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).